Breaking News Instant updates and real-time market news.

EPZM

Epizyme

06:31
11/28/16
11/28
06:31
11/28/16
06:31

Epizyme announces Fast Track designation for Tazemetostat in DLBCL

Epizyme announced advancements in the company's clinical programs evaluating tazemetostat, its first-in-class EZH2 inhibitor. The U.S. FDA has granted tazemetostat Fast Track designation in patients with diffuse large B-cell lymphoma with EZH2 activating mutations. Additionally, Epizyme is focusing its Phase 2 registration-enabling study in adult patients with genetically-defined solid tumors on those cancers marked by loss of INI1, and has expanded enrollment in the epithelioid sarcoma cohort of the study based on encouraging early activity in this patient population

  • 03

    Dec

EPZM Epizyme

04/05/16
04/05/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Epizyme (EPZM) initiated with a Buy at Citi by analyst Robyn Karnauskas, who said long-term platform valuation could come in 2017. 2. AT&T (T) initiated with an Outperform at Macquarie. 3. General Dynamics (GD) initiated with a Buy at Guggenheim. 4. Grainger (GWW) initiated with an Outperform at BMO Capital. 5. McDonald's (MCD) initiated with a Hold at Evercore ISI. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
06/20/16
RBCM
06/20/16
NO CHANGE
RBCM
Epizyme data could improve over time, says RBC Capital
After the overall response rate of refractory non-Hodgkin lymphoma patients taking Epizyme's Tazemetostat came in at 28%, down from 56% and 60% in prior trials, RBC Capital says that the data could improve over time. Specifically, the firm thinks that some of the patients whose tumors shrunk may become responsive over the longer term. Additionally, RBC Capital reports that there was a 100% overall response rate in the FL EZH2 mutant arm of the trial. The firm keeps an Outperform rating on the shares.
08/09/16
LEER
08/09/16
NO CHANGE
Target $39
LEER
Outperform
Epizyme weakness unwarranted, says Leerink
Leerink analyst Seamus Fernandez says Epizyme announced during its Q2 earnings call that it now plans to report results from its two ongoing Phase 2 trials of tazemetostat in the first half of 2017, rather than at medical conferences in late 2016 as previously anticipated. The analyst believes the delay may allow for data to mature and says the weakness in the stock is unwarranted. Fernandez reiterates an Outperform rating and $39 price target on the shares.
09/21/16
09/21/16
NO CHANGE

Epizyme collaborates with Foundation Medicine for tazemetostat Phase 2 trial
Epizyme (EPZM) has entered into a collaboration agreement with Foundation Medicine FMI) to support patient identification and enrollment for Epizyme's ongoing Phase 2 clinical trial of tazemetostat in patients with non-Hodgkin lymphoma. Foundation Medicine's SmartTrials Precision Enrollment Program and FoundationOne Heme panel will assist in identifying a population of individuals with NHL who harbor EZH2 mutations and constitute specific cohorts in the Epizyme trial. Tazemetostat is Epizyme's oral, first-in-class EZH2 inhibitor being investigated in multiple ongoing clinical trials. Early clinical data suggest tazemetostat has encouraging clinical activity and a favorable safety profile in patients with relapsed and refractory NHL.

TODAY'S FREE FLY STORIES

WLFC

Willis Lease

$26.66

0.05 (0.19%)

18:59
01/19/18
01/19
18:59
01/19/18
18:59
Hot Stocks
Willis Lease announces $1,000 bonus for employees »

Willis Lease announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DPS

Dr Pepper Snapple

$96.35

1.03 (1.08%)

18:13
01/19/18
01/19
18:13
01/19/18
18:13
Hot Stocks
Dr Pepper to become official sponsor of esports team TSM »

Dr Pepper announced it is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RCII

Rent-A-Center

$11.70

0.09 (0.78%)

17:53
01/19/18
01/19
17:53
01/19/18
17:53
Hot Stocks
Vintage Capital in standstill pact with Rent-A-Center »

On January 17, Vintage…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AR

Antero Resources

$18.74

-0.59 (-3.05%)

17:44
01/19/18
01/19
17:44
01/19/18
17:44
Recommendations
Antero Resources analyst commentary at MUFG »

Antero Resources price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

T

AT&T

$37.21

0.06 (0.16%)

, TWX

Time Warner

$93.36

0.39 (0.42%)

17:44
01/19/18
01/19
17:44
01/19/18
17:44
Periodicals
AT&T requesting docs from companies in Time Warner deal hearing, Reuters says »

AT&T (T) is…

T

AT&T

$37.21

0.06 (0.16%)

TWX

Time Warner

$93.36

0.39 (0.42%)

VZ

Verizon

$51.91

0.36 (0.70%)

CMCSA

Comcast

$42.50

0.65 (1.55%)

CMCSK

Comcast

DISH

Dish

$45.26

0.1 (0.22%)

CHTR

Charter

$366.05

0.8 (0.22%)

DIS

Disney

$110.59

0.17 (0.15%)

VIA

Viacom

$39.20

-0.5 (-1.26%)

VIAB

Viacom

$33.36

-0.59 (-1.74%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 24

    Jan

  • 24

    Jan

  • 31

    Jan

  • 02

    Feb

  • 06

    Feb

  • 08

    Feb

  • 08

    Feb

GRPN

Groupon

$5.57

0.46 (9.00%)

17:44
01/19/18
01/19
17:44
01/19/18
17:44
Hot Stocks
Groupon announces Chief Product Officer Jay Sullivan resigns »

On January 17, Jay…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CELG

Celgene

$102.65

0.93 (0.91%)

17:41
01/19/18
01/19
17:41
01/19/18
17:41
Hot Stocks
Celgene's Abraxane exceeds primary endpoint target in pancreatic cancer trial »

Celgene announced primary…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jan

  • 25

    Jan

  • 16

    Feb

  • 25

    Mar

VALU

Value Line

$19.60

0.3 (1.55%)

17:40
01/19/18
01/19
17:40
01/19/18
17:40
Hot Stocks
Value Line reaffirms $3M stock repurchase program »

The Board of Directors…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VALU

Value Line

$19.60

0.3 (1.55%)

17:39
01/19/18
01/19
17:39
01/19/18
17:39
Hot Stocks
Value Line declares special dividend of 20c per share »

Payable on March 9 to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ZEAL

Zealand Pharma

$15.05

-0.78 (-4.93%)

17:34
01/19/18
01/19
17:34
01/19/18
17:34
Hot Stocks
Zealand Pharma: FDA approves IND for Phase 3 trials of dasiglucagon in CHI »

The U.S. FDA has approved…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GNMSF

Genmab

$190.75

2.75 (1.46%)

, JNJ

Johnson & Johnson

$147.36

0.44 (0.30%)

17:29
01/19/18
01/19
17:29
01/19/18
17:29
Hot Stocks
Genmab says FDA grants priority review for daratumumab »

Genmab (GNMSF) announced…

GNMSF

Genmab

$190.75

2.75 (1.46%)

JNJ

Johnson & Johnson

$147.36

0.44 (0.30%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

  • 23

    Jan

  • 16

    Feb

  • 08

    Mar

HII

Huntington Ingalls

$242.12

5.24 (2.21%)

17:21
01/19/18
01/19
17:21
01/19/18
17:21
Hot Stocks
Huntington Ingalls awarded $125.2M government contract modification »

Huntington Ingalls Inc. -…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Feb

  • 21

    Feb

BAESY

BAE Systems

$33.30

0.18 (0.54%)

, GD

General Dynamics

$209.10

1.3 (0.63%)

17:20
01/19/18
01/19
17:20
01/19/18
17:20
Hot Stocks
BAE Systems, General Dynamics awarded $237.6M government contract modification »

BAE Systems (BAESY) San…

BAESY

BAE Systems

$33.30

0.18 (0.54%)

GD

General Dynamics

$209.10

1.3 (0.63%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

SYRS

Syros Pharmaceuticals

$10.80

0.27 (2.56%)

17:17
01/19/18
01/19
17:17
01/19/18
17:17
Syndicate
Breaking Syndicate news story on Syros Pharmaceuticals »

Syros Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WTFC

Wintrust Financial

$87.81

0.96 (1.11%)

17:13
01/19/18
01/19
17:13
01/19/18
17:13
Hot Stocks
Wintrust Financial raises its minimum wage to $15 per hour »

Wintrust Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

TWTR

Twitter

$23.66

-0.38 (-1.58%)

17:07
01/19/18
01/19
17:07
01/19/18
17:07
Hot Stocks
Twitter says has identified more IRA and automated Russia-based accounts »

In a statement on its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 07

    Feb

  • 08

    Feb

  • 28

    Feb

ITEK

Inotek Pharmaceuticals

17:04
01/19/18
01/19
17:04
01/19/18
17:04
Hot Stocks
Boxer Capital reports 5.3% passive stake in Rocket Pharmaceuticals »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OIS

Oil States

$32.80

0.35 (1.08%)

17:03
01/19/18
01/19
17:03
01/19/18
17:03
Syndicate
Breaking Syndicate news story on Oil States »

Oil States files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AVGO

Broadcom

$266.39

-3.41 (-1.26%)

, QCOM

Qualcomm

$68.04

-0.01 (-0.01%)

16:43
01/19/18
01/19
16:43
01/19/18
16:43
Hot Stocks
Broadcom receives second request from FTC for proposed Qualcomm deal »

Broadcom (AVGO) announced…

AVGO

Broadcom

$266.39

-3.41 (-1.26%)

QCOM

Qualcomm

$68.04

-0.01 (-0.01%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Mar

TRNC

tronc

$19.53

0.3 (1.56%)

16:37
01/19/18
01/19
16:37
01/19/18
16:37
Periodicals
LA Times' CEO Ross Levinsohn to take leave of absence amid probe, WSJ says »

Ross Levinsohn, the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AP

Ampco-Pittsburgh

$14.20

0.15 (1.07%)

16:35
01/19/18
01/19
16:35
01/19/18
16:35
Syndicate
Breaking Syndicate news story on Ampco-Pittsburgh »

Ampco-Pittsburgh files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Mar

CG

Carlyle Group

$24.35

-0.05 (-0.20%)

, UBSH

Union Bankshares

$38.79

0.54 (1.41%)

16:33
01/19/18
01/19
16:33
01/19/18
16:33
Hot Stocks
Carlyle Group reports 6% passive stake in Union Bankshares »

In a regulatory filing,…

CG

Carlyle Group

$24.35

-0.05 (-0.20%)

UBSH

Union Bankshares

$38.79

0.54 (1.41%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

ANDX

Andeavor Logistics

$52.52

0.12 (0.23%)

16:31
01/19/18
01/19
16:31
01/19/18
16:31
Hot Stocks
Andeavor Logistics raises quarterly cash distribution to $1.00 per unit »

The fourth quarter…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Feb

16:30
01/19/18
01/19
16:30
01/19/18
16:30
Options
Preliminary option volume of 22.8M today »

Preliminary option volume…

TRNC

tronc

$19.53

0.3 (1.56%)

16:26
01/19/18
01/19
16:26
01/19/18
16:26
Periodicals
LA Times' CEO Ross Levinsohn to take leave of absence amid probe, DJ says »

Dow Jones added that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.